secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0000899923-22-000022
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q4 revenue up 4% to $160.8M; GAAP EPS $(0.10), adjusted $(0.02)
-------------------------------------------------------------------------------

- Revenue $160.8M (+4% YoY); full-year $690.6M (+24%). Ex-divested businesses, Q4 revenue up 19%.
- GAAP diluted EPS $(0.10); adjusted EPS $(0.02); GAAP gross margin 71.5%, adjusted 71.8%.
- Hereditary cancer revenue $74.8M (-5% YoY); pharmacogenomics $29.4M (+63%); prenatal $30.1M (+43%).
- FY2022 guidance: revenue $670-700M, adjusted EPS $0.00-$0.20, adjusted gross margin 70-72%.
- Ended Q4 with $398.8M cash, no debt; Omicron variant adversely impacted hereditary cancer volumes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/0000899923-22-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/mygn-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer